Loss of smell as an early Alzheimer’s signal: what to know and what to do

If your sense of smell has been slipping—and it isn’t explained by a recent cold or allergies—it could be an early clue to Alzheimer’s disease. Research now suggests that odor-detection problems can arise years before memory issues, because the brain’s immune cells start dismantling smell-related nerve connections very early in the disease process.

What should you do? If smell loss is persistent (weeks to months), especially after age 60 or alongside a family history of dementia, talk with your clinician. Simple, low-cost smell tests, paired with cognitive screening and emerging blood biomarkers, can help determine whether further evaluation for Alzheimer’s is warranted.

The quick take

• Scientists have long noticed that many people with Alzheimer’s report smell loss early on. A recent study adds a key piece: immune cells in the brain appear to actively strip away smell-carrying nerve fibers when they detect abnormal molecular “flags” on those nerves.
• This pruning starts before noticeable memory decline, making smell testing a practical way to spot at-risk individuals sooner—though smell loss alone does not diagnose Alzheimer’s.
• If you notice a persistent, unexplained reduction in smell, seek evaluation. Doctors can combine smell testing with cognitive exams and, when appropriate, imaging or blood-based biomarkers.

Key terms (plain definitions)

• Olfactory system: the body’s smell apparatus, including the nose’s sensory lining (olfactory epithelium), the olfactory bulb at the base of the brain, and the brain regions that process odors.
• Hyposmia: reduced ability to smell. Anosmia means no smell; parosmia means distorted smells; phantosmia means smelling things that aren’t there.
• Microglia: the brain’s resident immune cells. They monitor and clean up debris, and can prune (remove) synapses and nerve fibers.
• Alzheimer’s pathology: abnormal protein changes—classically amyloid-beta plaques and tau tangles—that disrupt neuron function and connectivity.

What’s new in the science

For years, smell loss was observed as an early correlate of Alzheimer’s, but the “how” was blurry. New work reports that microglia—the brain’s immune sentinels—recognize abnormal signals on the surface of smell-related nerve fibers and begin clearing those fibers away. In other words, the immune system may be actively dismantling parts of the olfactory pathway early, rather than smell simply fading as a late, passive casualty of neurodegeneration.

Why it’s a big deal:

• Mechanism, not just correlation: A concrete cellular process helps explain why smell declines so early.
• Earlier flags: If the olfactory pathway is hit first, detecting smell changes could prompt earlier, better-timed interventions.
• New therapeutic angles: If overzealous immune pruning drives early damage, future drugs might aim to temper this response in targeted ways.

How the nose–brain pathway gets hit first

Smell signals start with olfactory sensory neurons in the upper nose. These neurons extend thin fibers through the skull into the olfactory bulb—a brain structure just above the nasal cavity. From there, signals fan out to memory and emotion hubs, including the hippocampus and limbic system. That close anatomical and functional link may explain why smell is intertwined with memory.

In early Alzheimer’s, abnormal protein changes can appear in olfactory structures. Microglia patrol these areas. When they encounter nerve fibers or synapses bearing unusual molecular patterns, they can tag and engulf them. That immune “cleanup” is essential during development and in injuries—but if it activates at the wrong time or place, healthy connections can be lost. The new findings suggest this pruning may begin in smell pathways long before a person forgets appointments or misplaces keys more than usual.

Who should pay attention

• Adults over 60 with a new, persistent reduction in smell
• People with a family history of Alzheimer’s or carriers of genetic risk such as APOE ε4
• Anyone with unexplained smell loss lasting more than 4–8 weeks, especially without sinus symptoms
• Individuals noticing smell changes alongside other subtle shifts: sleep disruptions, increasing forgetfulness, difficulty managing finances or new technology, or word-finding issues

Important: Smell loss is common and often benign—post-viral changes (including from COVID-19), allergies, sinus disease, smoking, head injury, and certain medications are frequent culprits. The key is persistence and lack of an obvious cause.

What to do if your sense of smell is fading

1. Rule out the obvious
   • Recent upper respiratory infection? Seasonal allergies? New medications (e.g., some antidepressants, antihypertensives)? Smoking or recent head injury?
   • If yes, monitor for 4–8 weeks; many cases improve as the underlying issue resolves.
2. Try a quick self-check (not a diagnosis)
   • Can you detect coffee, citrus peel, vinegar, cinnamon, or soap at close range? Note which are weak or absent and track changes weekly.
3. Make an appointment if it persists
   • Ask for a basic smell test. Clinicians can use validated tools like UPSIT (scratch-and-sniff) or Sniffin’ Sticks to get an objective score.
   • Request a brief cognitive screen (e.g., MoCA). Normal cognition does not rule out future risk, but it sets a baseline.
   • Discuss risk factors and whether additional evaluation makes sense for you.
4. When specialists may help
   • ENT evaluation if sinus disease, polyps, or structural nasal issues are suspected.
   • Neurology or memory clinic if you have compounding cognitive concerns, strong family history, or abnormal screening results.

How doctors may evaluate smell loss in the context of Alzheimer’s risk

• History and exam: Onset, triggers, infections, trauma, medications, exposures (e.g., solvents), and neurologic review.
• Objective smell testing: Standardized odor identification thresholds compared with age/sex norms.
• Cognitive screening: Brief tests for attention, memory, and executive function; depression screening, sleep assessment.
• Lab work: To rule out contributors such as thyroid issues or vitamin deficiencies when appropriate.
• Imaging and biomarkers (case-by-case):
  • MRI for structural brain changes.
  • PET scans for amyloid or tau (availability varies).
  • Cerebrospinal fluid assays for amyloid and phosphorylated tau.
  • Blood-based biomarkers (e.g., phosphorylated tau forms, amyloid ratios) are emerging and increasingly available in specialized clinics. These can support a risk assessment but are not yet universally used for diagnosis.

No single test makes the diagnosis. Clinicians synthesize symptoms, cognitive findings, and biomarkers over time.

Pros and cons of using smell as an early flag

• Pros
  • Noninvasive, low-cost, quick to administer
  • Can detect risk years before typical memory complaints
  • Useful as part of a multi-signal risk profile (smell + cognition + biomarkers)
• Cons
  • Not specific: Many non-Alzheimer’s causes of smell loss
  • Variability with age, culture, and testing method
  • Cannot, by itself, tell Alzheimer’s from other neurodegenerative diseases (e.g., Parkinson’s also affects smell early)

Other common causes of smell loss (and clues that point to them)

• Post-viral (including COVID-19): Sudden onset after illness; may feature parosmia (distorted smells). Often improves over months.
• Chronic sinus disease/allergies: Nasal congestion, facial pressure, fluctuating symptoms.
• Smoking or vaping: Gradual dulling; may improve with cessation.
• Head injury: Onset after trauma; may co-occur with taste change.
• Medications: Some blood pressure drugs, antidepressants, and others can dull smell.
• Parkinson’s disease: Prominent smell loss years before tremor or stiffness; constipation and sleep behavior disorder are common early clues.

What about taste?

Most people who say “food has no taste” actually mean smell is impaired—flavor largely depends on olfaction. True taste (sweet, salty, sour, bitter, umami) on the tongue can be intact even when flavors seem flat.

Can smell training help?

Smell (olfactory) training—sniffing a set of scents twice daily for months—can help recovery after viral smell loss. Whether it helps when smell pathways are affected by neurodegeneration is unclear. It’s safe and inexpensive, but expectations should be modest if Alzheimer’s or Parkinson’s is the underlying cause.

How to try it:

• Choose 4–6 distinct odors (e.g., rose, lemon, eucalyptus, clove, coffee, vinegar).
• Gently sniff each for ~20 seconds, twice daily, for 3–6 months.
• Keep a log; even small gains are encouraging.

What this means for prevention and timing of treatment

Smell testing won’t prevent Alzheimer’s, but it can flag risk earlier, when interventions may work best. Steps that support brain health are still worth pursuing regardless of cause:

• Move your body: Regular aerobic and strength activity supports brain blood flow and may slow cognitive decline.
• Care for your heart: Control blood pressure, blood sugar, and cholesterol.
• Prioritize sleep: Treat sleep apnea; aim for consistent, restorative sleep.
• Engage your mind and social life: Cognitive stimulation and social connection matter.
• Eat for brain health: Mediterranean-style patterns rich in plants, fish, and healthy fats.
• Hear well: If you have hearing loss, use hearing aids—hearing is linked to cognition.

As disease-modifying therapies evolve, earlier identification matters. If clinicians can spot likely Alzheimer’s in its “pre-symptom” window—via smell changes plus biomarkers—they can time treatments before widespread brain network damage occurs.

What could future care look like?

• Routine smell screening in primary care for adults over 60, similar to vision or hearing checks.
• Risk algorithms that combine smell scores, brief cognitive tests, genetics, and blood biomarkers to stratify who needs advanced imaging or early therapy.
• Targeted therapies that modulate microglial pruning or related immune pathways in olfactory regions, aiming to preserve connections without shutting down essential immune surveillance.

Key takeaways

• A persistent, unexplained decline in smell can precede Alzheimer’s by years.
• New research suggests brain immune cells actively dismantle smell-related nerve fibers early in the disease.
• Smell loss is not specific to Alzheimer’s; many benign causes exist. Use smell testing as one piece of a broader assessment.
• If smell loss lasts beyond a month or two without a clear cause—especially after age 60—seek evaluation. Early identification opens the door to better monitoring and, potentially, earlier treatment.

FAQ

• Is smell loss from COVID-19 the same as in Alzheimer’s?
  No. COVID-related smell loss is usually sudden and often improves over months; Alzheimer’s-related decline tends to be gradual and persistent. However, the experiences can overlap, so timing, associated symptoms, and testing help differentiate them.

• Can smell tests diagnose Alzheimer’s by themselves?
  No. They are screening tools. Diagnosis relies on a combination of cognitive assessment, clinical evaluation, and, when appropriate, biomarkers from blood, spinal fluid, or imaging.

• If I lose my sense of smell, will I definitely develop Alzheimer’s?
  No. Many people with hyposmia never develop dementia. Smell loss increases risk but is not destiny; it’s a reason to be evaluated and to optimize brain-health factors.

• Can I regain smell if Alzheimer’s is the cause?
  Significant recovery is less likely when neurodegeneration drives the loss, though fluctuations occur. Smell training is safe to try, and managing other contributors (e.g., sinus disease) can help.

• Are at-home scratch-and-sniff kits useful?
  They can provide a quick check and track changes over time, but clinical, validated tests interpreted by a professional are more reliable and comparable to norms.

• Does zinc, vitamin A, or caffeine restore smell?
  There’s no strong evidence that supplements or caffeine restore smell due to Alzheimer’s. Avoid high-dose zinc—it can be harmful. Discuss any supplements with your clinician.

Source & original reading: https://www.sciencedaily.com/releases/2026/04/260411043048.htm